Linda Stein Gold, MD, Director of Dermatology Clinical Research at Henry Ford Health System in Detroit, MI, reviews new data on atopic dermatitis (AD) patients who switched to lebrikizumab (Ebyglyss, Lilly) from dupilumab (Dupixent, Sanofi and Regeneron) that was presented at the 2024 Fall Clinical Dermatology Conference in Las Vegas, NV. “If you had an inadequate response to dupilumab, can you still get a good response with lebrikizumab? The answer was about half of the patients who had an inadequate response got a treatment success with lebrikizumab,” she says. “That tells us that these drugs are different. They are targeting different places.” In addition, patients who experienced side effects while taking dupilumab did not have the same side effects when they switched to lebrikizumab.
